Ultragenyx Pharmaceutical (RARE) Financials

$33.87 -1.16 (-3.31%)

Closing price 04:00 PM Eastern

Extended Trading

$34.03 +0.16 (+0.47%)

As of 07:34 PM Eastern

Annual Income Statements for Ultragenyx Pharmaceutical

This table shows Ultragenyx Pharmaceutical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Income / (Loss) Attributable to Common Shareholders	-569	-607	-707	-454	-187	-403	-198	-302	-246	-146
Consolidated Net Income / (Loss)	-569	-607	-707	-454	-187	-403	-198	-302	-246	-146
Net Income / (Loss) Continuing Operations	-569	-607	-707	-454	-187	-403	-198	-302	-246	-146
Total Pre-Tax Income	-568	-608	-702	-453	-185	-399	-197	-318	-246	-146
Total Operating Income	-536	-569	-649	-382	-330	-424	-371	-329	-248	-148
Total Gross Profit	484	389	335	335	265	95	50	2.61	0.13	0.00
Total Revenue	560	434	363	351	271	104	51	2.61	0.13	0.00
Operating Revenue	560	434	363	351	271	104	51	2.61	0.13	0.00
Total Cost of Revenue	77	45	28	16	6.13	9.01	1.15	0.00	0.00	0.00
Operating Cost of Revenue	77	45	28	16	6.13	9.01	1.15	0.00	0.00	0.00
Total Operating Expenses	1,019	958	984	717	595	519	422	332	248	148
Selling, General & Admin Expense	322	310	278	220	183	162	128	100	65	33
Research & Development Expense	698	648	706	497	412	357	294	232	183	115
Total Other Income / (Expense), net	-32	-39	-53	-71	145	25	174	11	2.17	2.12
Interest Expense	63	66	43	29	33	1.14	0.00	0.00	-	-
Interest & Investment Income	35	27	-8.23	-40	177	27	9.54	4.07	3.79	2.32
Other Income / (Expense), net	-3.96	-0.34	-1.57	-1.69	0.61	-0.79	165	6.53	-1.62	-0.20
Income Tax Expense	1.60	-1.83	5.70	1.04	1.21	3.28	0.51	-16	0.04	0.00
Basic Earnings per Share	($6.29)	($8.25)	($10.12)	($6.70)	($3.07)	($7.12)	($3.97)	($7.12)	($6.21)	($3.96)
Weighted Average Basic Shares Outstanding	90.54M	73.54M	69.91M	67.80M	60.85M	56.58M	49.78M	42.45M	39.59M	36.78M
Diluted Earnings per Share	($6.29)	($8.25)	($10.12)	($6.70)	($3.07)	($7.12)	($3.97)	($7.12)	($6.21)	($3.96)
Weighted Average Diluted Shares Outstanding	90.54M	73.54M	69.91M	67.80M	60.85M	56.58M	49.78M	42.45M	39.59M	36.78M
Weighted Average Basic & Diluted Shares Outstanding	92.50M	82.34M	70.22M	67.80M	60.85M	56.58M	49.78M	42.45M	39.59M	36.78M

This table shows Ultragenyx Pharmaceutical's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-151	-133	-134	-132	-171	-123	-160	-160	-164	-152	-245
Consolidated Net Income / (Loss)	-151	-133	-134	-132	-171	-123	-160	-160	-164	-152	-245
Net Income / (Loss) Continuing Operations	-151	-133	-134	-132	-171	-123	-160	-160	-164	-152	-245
Total Pre-Tax Income	-150	-133	-133	-131	-170	-127	-159	-159	-163	-153	-239
Total Operating Income	-143	-122	-132	-116	-165	-122	-145	-148	-154	-146	-225
Total Gross Profit	111	148	118	126	91	115	87	98	88	98	82
Total Revenue	139	165	139	147	109	127	98	108	100	103	91
Operating Revenue	139	165	139	147	109	127	98	108	100	103	91
Total Cost of Revenue	29	17	21	21	18	12	11	9.91	12	5.32	8.63
Operating Cost of Revenue	29	17	21	21	18	12	11	9.91	12	5.32	8.63
Total Operating Expenses	254	270	250	242	257	237	232	246	242	244	307
Selling, General & Admin Expense	88	82	80	81	78	77	75	81	77	73	70
Research & Development Expense	166	188	170	162	178	161	157	165	166	171	237
Total Other Income / (Expense), net	-6.83	-11	-1.23	-14	-4.88	-4.84	-14	-11	-9.37	-7.66	-14
Interest Expense	14	16	16	16	16	17	18	15	16	16	15
Interest & Investment Income	6.67	8.00	11	3.41	13	10	4.46	6.23	5.96	8.04	1.86
Other Income / (Expense), net	0.84	-3.61	3.08	-1.83	-1.61	2.04	-0.70	-1.99	0.31	0.18	-1.11
Income Tax Expense	1.31	-0.02	0.30	0.86	0.46	-3.70	0.65	0.73	0.50	-1.45	6.29
Basic Earnings per Share	($1.57)	($1.34)	($1.40)	($1.52)	($2.03)	($1.44)	($2.23)	($2.25)	($2.33)	($2.17)	($3.50)
Weighted Average Basic Shares Outstanding	96.29M	90.54M	95.49M	86.58M	84.29M	73.54M	71.66M	70.90M	70.37M	69.91M	70.05M
Diluted Earnings per Share	($1.57)	($1.34)	($1.40)	($1.52)	($2.03)	($1.44)	($2.23)	($2.25)	($2.33)	($2.17)	($3.50)
Weighted Average Diluted Shares Outstanding	96.29M	90.54M	95.49M	86.58M	84.29M	73.54M	71.66M	70.90M	70.37M	69.91M	70.05M
Weighted Average Basic & Diluted Shares Outstanding	94.54M	92.50M	92.34M	92.17M	83.13M	82.34M	82.11M	71.49M	70.81M	70.22M	70.11M

This table details how cash moves in and out of Ultragenyx Pharmaceutical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Change in Cash & Equivalents	-35	82	-172	-417	290	321	13	-62	69	69
Net Cash From Operating Activities	-414	-475	-380	-339	-132	-345	-291	-254	-161	-106
Net Cash From Continuing Operating Activities	-414	-475	-384	-339	-132	-345	-291	-254	-161	-106
Net Income / (Loss) Continuing Operations	-569	-607	-707	-454	-187	-403	-198	-302	-246	-146
Consolidated Net Income / (Loss)	-569	-607	-707	-454	-187	-403	-198	-302	-246	-146
Depreciation Expense	36	26	18	13	12	8.54	20	5.83	3.42	1.38
Amortization Expense	-13	-13	2.70	6.61	0.85	-6.21	-2.64	1.71	4.84	5.64
Non-Cash Adjustments To Reconcile Net Income	118	134	246	101	3.14	72	-85	61	50	25
Changes in Operating Assets and Liabilities, net	14	-15	56	-5.74	38	-17	-25	-20	26	7.74
Net Cash From Investing Activities	-18	168	-292	-195	-179	-13	-33	55	91	-292
Net Cash From Continuing Investing Activities	-18	168	-292	-195	-179	-13	-33	55	91	-292
Purchase of Property, Plant & Equipment	-7.49	-44	-116	-73	-44	-25	-4.08	-2.79	-10	-4.96
Acquisitions	-13	-2.50	-105	0.00	-37	-14	0.00	-143	0.00	0.00
Purchase of Investments	-409	-526	-615	-1,012	-813	-693	-510	-230	-442	-624
Sale and/or Maturity of Investments	413	746	545	891	721	719	310	432	544	338
Other Investing Activities, net	-2.44	-5.05	-0.84	-0.94	-5.56	0.00	0.00	-	-	-1.54
Net Cash From Financing Activities	399	388	501	119	600	679	337	136	139	468
Net Cash From Continuing Financing Activities	399	388	501	119	600	679	337	136	139	468
Repayment of Debt	0.00	-0.03	-0.56	-0.49	-0.24	0.00	0.00	-4.94	0.00	0.00
Issuance of Common Equity	399	388	11	119	601	365	337	141	139	468
Other Financing Activities, net	0.00	0.00	491	0.00	0.00	314	0.00	0.00	-	-
Effect of Exchange Rate Changes	-2.53	0.46	-1.08	-1.19	1.12	-0.17	-	0.53	-0.07	0.00

This table details how cash moves in and out of Ultragenyx Pharmaceutical's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-45	24	-330	368	-97	141	-29	16	-46	-259	234
Net Cash From Operating Activities	-166	-80	-67	-77	-191	-84	-118	-116	-157	-90	-95
Net Cash From Continuing Operating Activities	-166	-80	-67	-77	-191	-84	-118	-116	-157	-94	-95
Net Income / (Loss) Continuing Operations	-151	-133	-134	-132	-171	-123	-160	-160	-164	-152	-245
Consolidated Net Income / (Loss)	-151	-133	-134	-132	-171	-123	-160	-160	-164	-152	-245
Depreciation Expense	8.99	9.08	8.76	8.86	8.85	8.22	7.19	5.36	5.24	4.96	4.69
Amortization Expense	-1.73	-2.81	-3.12	-2.95	-3.76	-3.95	-2.68	-3.22	-2.99	-1.65	0.97
Non-Cash Adjustments To Reconcile Net Income	34	25	30	32	31	22	34	34	43	36	122
Changes in Operating Assets and Liabilities, net	-57	23	31	16	-56	13	2.80	7.16	-38	18	22
Net Cash From Investing Activities	120	103	-276	61	94	-107	64	99	111	-172	-162
Net Cash From Continuing Investing Activities	120	103	-276	61	94	-107	64	99	111	-172	-162
Purchase of Property, Plant & Equipment	-1.32	-0.65	-1.62	-2.01	-3.21	-1.60	-3.70	-14	-25	-27	-26
Acquisitions	-15	-	-	-2.50	-10	-	-	-2.50	0.00	0.37	-75
Purchase of Investments	0.00	-16	-367	-3.37	-22	-222	-139	-103	-62	-199	-211
Sale and/or Maturity of Investments	137	119	94	68	132	116	208	220	202	54	151
Other Investing Activities, net	-0.78	-0.13	-0.20	-0.04	-2.07	-0.27	-0.43	-0.40	-3.95	-0.60	-0.18
Net Cash From Financing Activities	0.16	3.19	11	385	-0.06	331	25	33	-0.72	1.88	492
Net Cash From Continuing Financing Activities	0.16	3.19	11	385	-0.06	331	25	33	-0.72	1.88	492
Repayment of Debt	0.00	-	-	-	0.00	-	-	-0.06	0.03	-0.12	-0.15
Issuance of Common Equity	0.16	3.19	11	385	-0.06	331	25	33	-0.75	2.00	1.07
Effect of Exchange Rate Changes	1.45	-2.47	1.28	-0.65	-0.68	1.10	-0.72	-0.14	0.21	1.35	-1.08

This table presents Ultragenyx Pharmaceutical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Total Assets	1,503	1,491	1,545	1,522	1,760	1,135	720	491	541	560
Total Current Assets	817	732	884	857	1,295	851	522	270	402	450
Cash & Equivalents	174	214	133	308	714	434	113	100	161	94
Short-Term Investments	436	364	615	433	488	322	346	134	219	343
Accounts Receivable	122	73	40	28	23	33	13	5.17	0.00	-
Inventories, net	45	34	27	16	13	12	7.07	0.76	0.00	-
Prepaid Expenses	40	48	-	72	58	51	43	29	20	13
Other Current Assets	0.00	0.00	69	-	-	-	-	-	-	-
Plant, Property, & Equipment, net	266	291	260	141	74	44	20	22	17	7.37
Total Noncurrent Assets	420	468	402	525	391	240	177	199	122	102
Long-Term Investments	135	200	149	294	11	5.17	0.00	9.98	118	99
Goodwill	44	44	44	44	44	44	44	44	0.00	-
Intangible Assets	178	166	160	131	131	129	129	142	0.00	-
Other Noncurrent Operating Assets	63	58	48	55	205	62	3.51	3.41	1.84	0.60
Total Liabilities & Shareholders' Equity	1,503	1,491	1,545	1,522	1,760	1,135	720	491	541	560
Total Liabilities	1,241	1,216	1,193	600	605	482	111	107	67	28
Total Current Liabilities	344	280	261	181	190	103	75	71	60	28
Accounts Payable	39	42	43	17	13	13	12	8.89	5.36	2.94
Accrued Expenses	241	196	205	146	108	83	62	62	55	25
Other Current Liabilities	64	42	13	19	68	7.24	0.00	-	-	-
Total Noncurrent Liabilities	897	935	932	418	416	378	36	36	6.39	0.56
Noncurrent Deferred & Payable Income Tax Liabilities	30	30	32	33	33	33	31	31	0.00	-
Other Noncurrent Operating Liabilities	867	905	900	385	382	345	4.76	5.12	6.39	0.56
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	7.00	0.00	-	-	-	-	-	-	-	-
Total Equity & Noncontrolling Interests	255	275	352	923	1,154	654	609	383	474	531
Total Preferred & Common Equity	255	275	352	923	1,154	654	609	383	474	531
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	255	275	352	923	1,154	654	609	383	474	531
Common Stock	4,213	3,662	3,140	2,998	2,773	2,087	1,640	1,222	1,004	817
Retained Earnings	-3,957	-3,388	-2,781	-2,074	-1,620	-1,433	-1,030	-833	-531	-285
Treasury Stock	-3.59	-0.43	0.00	-	-	-	-	-	-	-
Accumulated Other Comprehensive Income / (Loss)	-0.64	0.65	-6.57	-1.40	0.69	-0.15	-0.63	-5.68	0.91	-0.87
Other Equity Adjustments	3.59	0.43	0.00	-	-	-	-	-	-	-

This table presents Ultragenyx Pharmaceutical's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	1,312	1,538	1,618	1,307	1,238	1,311	1,383	1,618
Total Current Assets	699	800	965	596	599	702	766	1,013
Cash & Equivalents	127	151	481	112	73	102	86	392
Short-Term Investments	367	471	283	300	370	450	544	497
Accounts Receivable	99	93	106	100	79	71	43	31
Inventories, net	46	43	40	36	32	28	27	22
Prepaid Expenses	60	-	-	0.00	46	51	67	71
Plant, Property, & Equipment, net	261	272	279	285	297	289	278	235
Total Noncurrent Assets	352	466	375	426	342	320	339	371
Long-Term Investments	69	203	111	157	86	72	90	121
Goodwill	44	44	44	44	44	44	44	44
Intangible Assets	177	165	166	165	157	158	159	158
Other Noncurrent Operating Assets	62	54	54	60	54	46	45	47
Total Liabilities & Shareholders' Equity	1,312	1,538	1,618	1,307	1,238	1,311	1,383	1,618
Total Liabilities	1,161	1,185	1,186	1,167	1,206	1,182	1,163	1,150
Total Current Liabilities	292	285	273	246	254	244	218	227
Accounts Payable	47	36	60	41	33	42	59	24
Accrued Expenses	173	185	154	149	179	168	144	189
Other Current Liabilities	71	64	59	55	42	35	15	15
Total Noncurrent Liabilities	869	900	913	921	952	938	945	922
Noncurrent Deferred & Payable Income Tax Liabilities	30	30	30	30	32	32	32	33
Other Noncurrent Operating Liabilities	839	869	883	891	921	906	913	889
Redeemable Noncontrolling Interest	7.00	7.00	-	-	-	-	-	-
Total Equity & Noncontrolling Interests	144	347	432	140	32	129	220	469
Total Preferred & Common Equity	144	347	432	140	32	129	220	469
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	144	347	432	140	32	129	220	469
Common Stock	4,253	4,169	4,123	3,699	3,298	3,237	3,169	3,108
Retained Earnings	-4,108	-3,823	-3,690	-3,558	-3,264	-3,105	-2,945	-2,629
Treasury Stock	-7.57	-3.56	-3.40	-3.33	-0.38	-0.38	-0.36	-
Accumulated Other Comprehensive Income / (Loss)	-0.34	0.90	-1.10	-0.43	-2.24	-3.10	-3.97	-10
Other Equity Adjustments	7.57	3.56	3.40	3.33	0.38	0.38	0.36	-

This table displays calculated financial ratios and metrics derived from Ultragenyx Pharmaceutical's official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	29.01%	19.52%	3.39%	29.66%	161.32%	101.41%	1,871.48%	1,863.91%	0.00%	0.00%
EBITDA Growth	7.08%	11.62%	-73.16%	-14.91%	25.14%	-122.74%	39.74%	-30.46%	-71.28%	-151.07%
EBIT Growth	5.20%	12.44%	-69.65%	-16.36%	22.46%	-105.65%	35.91%	-29.16%	-68.74%	-144.89%
NOPAT Growth	5.84%	12.28%	-69.99%	-15.64%	22.17%	-14.22%	-12.90%	-32.63%	-67.87%	-160.20%
Net Income Growth	6.17%	14.25%	-55.81%	-143.36%	53.67%	-103.80%	34.60%	-22.88%	-68.85%	-143.50%
EPS Growth	23.76%	18.48%	-51.04%	-118.24%	56.88%	-79.35%	44.24%	-14.65%	-56.82%	-76.00%
Operating Cash Flow Growth	12.77%	-24.80%	-12.33%	-156.16%	61.72%	-18.87%	-14.47%	-57.69%	-51.90%	-137.44%
Free Cash Flow Firm Growth	10.62%	-1,951.27%	89.93%	23.81%	-581.75%	84.80%	31.92%	-158.66%	-54.59%	-170.01%
Invested Capital Growth	3.78%	7.82%	-388.14%	-93.35%	45.93%	-171.47%	7.35%	603.14%	-270.74%	-126.75%
Revenue Q/Q Growth	7.17%	5.86%	5.81%	-2.27%	26.01%	22.91%	36.78%	1,186.70%	3.91%	0.00%
EBITDA Q/Q Growth	-0.76%	4.53%	-7.66%	-1.48%	0.44%	-1.26%	3.92%	-8.81%	-7.42%	-37.13%
EBIT Q/Q Growth	-1.10%	4.28%	-6.99%	-1.91%	-0.45%	-0.95%	3.89%	-8.96%	-6.86%	-36.06%
NOPAT Q/Q Growth	-0.04%	3.98%	-7.11%	-1.73%	-0.50%	-0.98%	1.72%	-8.68%	-6.16%	-36.14%
Net Income Q/Q Growth	-1.82%	4.51%	-4.33%	-27.69%	27.23%	-1.51%	-3.18%	-3.58%	-6.99%	-35.92%
EPS Q/Q Growth	1.56%	8.13%	-4.01%	-28.35%	30.07%	2.33%	2.70%	-2.01%	-4.90%	-34.69%
Operating Cash Flow Q/Q Growth	1.05%	1.34%	-10.45%	2.34%	6.76%	-4.92%	8.20%	-15.54%	-4.71%	-35.89%
Free Cash Flow Firm Q/Q Growth	1.62%	4.06%	-192.68%	46.31%	-237.43%	87.90%	40.85%	-99.07%	-2.76%	-36.80%
Invested Capital Q/Q Growth	-2.52%	-1.05%	-0.56%	-18.73%	74.78%	-152.00%	-6.46%	524.54%	-36.50%	-23.69%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	86.30%	89.59%	92.21%	95.44%	97.74%	91.31%	97.77%	99.96%	100.00%	0.00%
EBITDA Margin	-92.29%	-128.12%	-173.28%	-103.46%	-116.74%	-407.50%	-368.47%	-12,055.17%	-181,475.19%	0.00%
Operating Margin	-95.67%	-131.08%	-178.60%	-108.63%	-121.80%	-408.98%	-721.18%	-12,593.49%	-186,471.43%	0.00%
EBIT Margin	-96.38%	-131.16%	-179.03%	-109.11%	-121.58%	-409.74%	-401.28%	-12,343.49%	-187,690.23%	0.00%
Profit (Net Income) Margin	-101.60%	-139.70%	-194.71%	-129.20%	-68.84%	-388.31%	-383.75%	-11,567.34%	-184,867.67%	0.00%
Tax Burden Percent	100.28%	99.70%	100.81%	100.23%	100.65%	100.82%	100.26%	94.91%	100.01%	100.00%
Interest Burden Percent	105.12%	106.83%	107.88%	118.14%	56.25%	94.00%	95.38%	98.74%	98.48%	98.43%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	-1,395.24%	-180.41%	-413.53%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	-1,377.90%	-198.12%	-394.26%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	1,331.45%	140.58%	343.06%	0.00%	0.00%
Return on Equity (ROE)	-211.71%	-193.23%	-110.96%	-43.72%	-20.64%	-63.79%	-39.83%	-70.48%	-48.93%	-40.67%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-187.50%	-285.55%	0.00%	0.00%
Operating Return on Assets (OROA)	-36.06%	-37.51%	-42.41%	-23.37%	-22.76%	-45.82%	-34.15%	-62.52%	-45.38%	0.00%
Return on Assets (ROA)	-38.02%	-39.96%	-46.12%	-27.67%	-12.89%	-43.42%	-32.65%	-58.59%	-44.70%	0.00%
Return on Common Equity (ROCE)	-208.95%	-193.23%	-110.96%	-43.72%	-20.64%	-63.79%	-39.83%	-70.48%	-48.93%	-40.67%
Return on Equity Simple (ROE_SIMPLE)	-222.95%	-220.26%	-200.69%	-49.21%	-16.16%	-61.60%	-32.45%	-78.79%	-51.88%	-27.42%
Net Operating Profit after Tax (NOPAT)	-375	-398	-454	-267	-231	-297	-260	-230	-174	-103
NOPAT Margin	-66.97%	-91.76%	-125.02%	-76.04%	-85.26%	-286.29%	-504.83%	-8,815.44%	-130,530.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-25.49%	-24.88%	-26.23%	-16.63%	4.51%	-17.34%	17.71%	-19.27%	-13.90%	-11.61%
Return On Investment Capital (ROIC_SIMPLE)	-146.96%	-144.67%	-128.87%	-	-	-	-	-	-	-
Cost of Revenue to Revenue	13.70%	10.41%	7.79%	4.56%	2.26%	8.69%	2.23%	0.04%	0.00%	0.00%
SG&A Expenses to Revenue	57.41%	71.34%	76.55%	62.60%	67.50%	155.74%	248.03%	3,825.00%	48,824.06%	0.00%
R&D to Revenue	124.57%	149.33%	194.26%	141.48%	152.04%	344.56%	570.93%	8,868.45%	137,747.37%	0.00%
Operating Expenses to Revenue	181.97%	220.67%	270.81%	204.08%	219.54%	500.30%	818.96%	12,693.45%	186,571.43%	0.00%
Earnings before Interest and Taxes (EBIT)	-540	-570	-650	-383	-330	-425	-207	-322	-250	-148
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-517	-556	-630	-364	-316	-423	-190	-315	-241	-141
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	15.22	14.26	9.21	6.21	7.32	3.77	3.61	5.15	6.06	8.20
Price to Tangible Book Value (P/TBV)	119.25	60.66	21.95	7.67	8.63	5.14	5.05	10.00	6.06	8.20
Price to Revenue (P/Rev)	6.93	9.04	8.94	16.31	31.18	23.79	42.71	756.23	21,600.43	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	11.66	12.45	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	5.62	7.25	6.47	13.37	26.71	16.46	33.78	662.64	17,844.62	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-2.83	-2.67	-1.51	-1.08	-1.09	-0.97	-0.71	-0.87	-1.03	-1.02
Leverage Ratio	5.57	4.84	2.41	1.58	1.60	1.47	1.22	1.20	1.09	1.06
Compound Leverage Factor	5.85	5.17	2.60	1.87	0.90	1.38	1.16	1.19	1.08	1.04
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	2.67%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	97.33%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-2.24	-1.85	-1.56	3.76	7.38	0.95	9.79	6.99	23.72	91.10
Noncontrolling Interest Sharing Ratio	1.30%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.37	2.61	3.38	4.72	6.83	8.24	6.99	3.80	6.67	16.13
Quick Ratio	2.13	2.32	3.02	4.24	6.46	7.63	6.32	3.37	6.31	15.65
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-394	-441	-21	-213	-280	-41	-270	-397	-153	-99
Operating Cash Flow to CapEx	-5,529.14%	-1,072.60%	-327.64%	-463.38%	-301.15%	-1,390.88%	-7,128.70%	-9,088.54%	-1,580.05%	-2,138.79%
Free Cash Flow to Firm to Interest Expense	-6.25	-6.68	-0.50	-7.25	-8.41	-36.19	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	-6.57	-7.19	-8.84	-11.51	-3.97	-304.30	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-6.69	-7.86	-11.54	-14.00	-5.29	-326.18	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.37	0.29	0.24	0.21	0.19	0.11	0.09	0.01	0.00	0.00
Accounts Receivable Turnover	5.74	7.63	10.55	13.64	9.69	4.55	5.75	0.00	0.00	0.00
Inventory Turnover	1.94	1.49	1.32	1.09	0.50	0.97	0.29	0.00	0.00	0.00
Fixed Asset Turnover	2.01	1.58	1.81	3.27	4.60	3.22	2.46	0.13	0.01	0.00
Accounts Payable Turnover	1.90	1.06	0.94	1.07	0.48	0.72	0.11	0.00	0.00	0.00
Days Sales Outstanding (DSO)	63.59	47.84	34.60	26.76	37.67	80.21	63.48	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	187.85	245.18	277.08	333.80	732.32	377.05	1,245.65	0.00	0.00	0.00
Days Payable Outstanding (DPO)	192.35	344.69	389.31	342.71	768.05	509.45	3,369.88	2,600,625.00	0.00	0.00
Cash Conversion Cycle (CCC)	59.08	-51.68	-77.63	17.84	1.93	-52.19	-2,060.75	-2,600,625.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-483	-502	-544	-111	-58	-107	149	139	-28	-7.45
Invested Capital Turnover	-1.14	-0.83	-1.11	-4.15	-3.30	4.87	0.36	0.05	-0.01	0.00
Increase / (Decrease) in Invested Capital	19	43	-433	-54	49	-256	10	167	-20	-4.17
Enterprise Value (EV)	3,147	3,150	2,351	4,698	7,238	1,707	1,739	1,731	2,373	3,820
Market Capitalization	3,885	3,927	3,248	5,732	8,450	2,467	2,199	1,975	2,873	4,356
Book Value per Share	$2.76	$3.35	$5.03	$13.53	$18.91	$11.32	$12.04	$9.00	$11.60	$13.68
Tangible Book Value per Share	$0.35	$0.79	$2.11	$10.96	$16.04	$8.31	$8.61	$4.64	$11.60	$13.68
Total Capital	262	275	352	923	1,154	654	609	383	474	531
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-745	-777	-897	-1,034	-1,212	-760	-460	-244	-500	-536
Capital Expenditures (CapEx)	7.49	44	116	73	44	25	4.08	2.79	10	4.96
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-137	-125	-125	-65	-96	-7.51	-12	-36	-40	-15
Debt-free Net Working Capital (DFNWC)	473	452	623	675	1,106	748	448	199	341	422
Net Working Capital (NWC)	473	452	623	675	1,106	748	448	199	341	422
Net Nonoperating Expense (NNE)	194	208	253	187	-45	106	-62	72	72	42
Net Nonoperating Obligations (NNO)	-745	-777	-897	-1,034	-1,212	-760	-460	-244	-502	-539
Total Depreciation and Amortization (D&A)	23	13	21	20	13	2.33	17	7.53	8.27	7.02
Debt-free, Cash-free Net Working Capital to Revenue	-24.46%	-28.89%	-34.42%	-18.49%	-35.36%	-7.24%	-23.42%	-1,375.34%	-30,167.67%	0.00%
Debt-free Net Working Capital to Revenue	84.42%	104.03%	171.38%	192.15%	407.96%	720.94%	869.30%	7,602.18%	256,718.80%	0.00%
Net Working Capital to Revenue	84.42%	104.03%	171.38%	192.15%	407.96%	720.94%	869.30%	7,602.18%	256,718.80%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($6.29)	($8.25)	($10.12)	($6.70)	($3.07)	($7.12)	($3.97)	($7.12)	($6.21)	($3.96)
Adjusted Weighted Average Basic Shares Outstanding	90.54M	73.54M	69.91M	69.38M	66.95M	57.89M	51.28M	49.61M	41.73M	38.98M
Adjusted Diluted Earnings per Share	($6.29)	($8.25)	($10.12)	($6.70)	($3.07)	($7.12)	($3.97)	($7.12)	($6.21)	($3.96)
Adjusted Weighted Average Diluted Shares Outstanding	90.54M	73.54M	69.91M	69.38M	66.95M	57.89M	51.28M	49.61M	41.73M	38.98M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	($6.70)	($3.07)	($7.12)	($3.97)	($7.12)	($6.21)	($3.96)
Adjusted Weighted Average Basic & Diluted Shares Outstanding	92.50M	82.34M	70.22M	67.80M	60.85M	56.58M	49.78M	42.45M	39.59M	36.78M
Normalized Net Operating Profit after Tax (NOPAT)	-375	-398	-454	-267	-231	-297	-260	-230	-174	-103
Normalized NOPAT Margin	-66.97%	-91.76%	-125.02%	-76.04%	-85.26%	-286.29%	-504.83%	-8,815.44%	-130,530.00%	0.00%
Pre Tax Income Margin	-101.31%	-140.12%	-193.14%	-128.91%	-68.39%	-385.14%	-382.75%	-12,187.52%	-184,841.35%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-8.56	-8.63	-15.12	-13.03	-9.90	-374.41	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	-5.95	-6.04	-10.56	-9.08	-6.94	-261.60	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-8.68	-9.30	-17.82	-15.52	-11.22	-396.29	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-6.07	-6.71	-13.26	-11.57	-8.26	-283.48	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Ultragenyx Pharmaceutical's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	27.99%	29.42%	42.27%	35.75%	8.30%	23.27%	8.10%	21.23%	25.72%	23.93%	11.09%
EBITDA Growth	16.69%	-3.35%	12.75%	24.04%	-6.80%	18.58%	35.93%	-8.24%	-16.26%	-46.04%	-159.31%
EBIT Growth	14.88%	-4.90%	11.58%	21.18%	-8.55%	17.49%	35.54%	-5.21%	-12.80%	-41.25%	-150.62%
NOPAT Growth	13.55%	-0.19%	9.04%	21.35%	-7.30%	16.19%	35.53%	-4.49%	-12.79%	-41.99%	-150.55%
Net Income Growth	11.49%	-8.28%	16.37%	17.66%	-4.09%	18.86%	34.87%	-1.05%	-7.65%	-23.99%	-235.77%
EPS Growth	22.66%	6.94%	37.22%	32.44%	12.88%	33.64%	36.29%	0.44%	-6.39%	-21.91%	-224.07%
Operating Cash Flow Growth	12.72%	5.25%	43.16%	33.74%	-21.59%	7.13%	-23.63%	-50.36%	-33.48%	-66.24%	-59.84%
Free Cash Flow Firm Growth	37.47%	18.30%	19.32%	-136.94%	-149.90%	-138.69%	-150.48%	305.87%	282.05%	1,941.31%	246.61%
Invested Capital Growth	3.88%	3.78%	5.16%	10.65%	14.20%	7.82%	8.26%	-1,665.62%	-2,765.65%	-388.14%	-476.35%
Revenue Q/Q Growth	-15.52%	18.20%	-5.12%	35.09%	-14.57%	29.92%	-9.47%	7.77%	-2.76%	13.94%	1.52%
EBITDA Q/Q Growth	-12.74%	2.97%	-9.79%	30.64%	-39.86%	18.08%	4.41%	2.48%	-6.62%	35.54%	-61.48%
EBIT Q/Q Growth	-12.88%	2.35%	-9.07%	29.21%	-39.12%	17.69%	2.77%	2.50%	-5.74%	35.69%	-58.69%
NOPAT Q/Q Growth	-16.90%	7.36%	-13.43%	29.63%	-35.48%	15.88%	1.93%	3.99%	-5.82%	35.30%	-58.95%
Net Income Q/Q Growth	-13.27%	0.10%	-1.46%	22.90%	-38.55%	22.84%	0.11%	2.53%	-8.00%	38.05%	-54.97%
EPS Q/Q Growth	-17.16%	4.29%	7.89%	25.12%	-40.97%	35.43%	0.89%	3.43%	-7.37%	38.00%	-54.87%
Operating Cash Flow Q/Q Growth	-109.39%	-18.67%	12.95%	59.65%	-127.32%	28.82%	-1.47%	25.95%	-73.64%	5.25%	-23.41%
Free Cash Flow Firm Q/Q Growth	-11.61%	11.40%	12.04%	28.11%	-45.83%	12.51%	-140.27%	-2.89%	13.05%	14.17%	264.24%
Invested Capital Q/Q Growth	14.70%	-2.52%	-6.51%	-3.19%	14.61%	-1.05%	-0.35%	0.90%	8.26%	-0.56%	-1,831.25%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	79.42%	89.75%	84.93%	85.53%	83.89%	90.54%	88.79%	90.85%	87.80%	94.85%	90.48%
EBITDA Margin	-96.81%	-72.55%	-88.37%	-76.36%	-148.73%	-90.85%	-144.09%	-136.47%	-150.81%	-137.54%	-243.11%
Operating Margin	-102.62%	-74.16%	-94.62%	-79.14%	-151.93%	-95.81%	-147.98%	-136.61%	-153.34%	-140.91%	-248.14%
EBIT Margin	-102.02%	-76.35%	-92.41%	-80.39%	-153.40%	-94.20%	-148.69%	-138.44%	-153.04%	-140.74%	-249.35%
Profit (Net Income) Margin	-108.46%	-80.90%	-95.71%	-89.51%	-156.83%	-96.70%	-162.82%	-147.57%	-163.16%	-146.91%	-270.23%
Tax Burden Percent	100.87%	99.99%	100.23%	100.66%	100.27%	97.08%	100.41%	100.46%	100.30%	99.05%	102.63%
Interest Burden Percent	105.40%	105.97%	103.34%	110.62%	101.96%	105.74%	109.06%	106.10%	106.29%	105.39%	105.59%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-377.06%	-211.71%	-289.98%	-208.43%	-340.05%	-193.23%	-253.84%	-178.60%	-141.42%	-110.96%	-96.69%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-46.02%	-28.57%	-34.80%	-26.41%	-50.47%	-26.94%	-42.70%	-42.38%	-42.46%	-33.34%	-55.18%
Return on Assets (ROA)	-48.93%	-30.27%	-36.04%	-29.41%	-51.60%	-27.66%	-46.76%	-45.17%	-45.27%	-34.80%	-59.80%
Return on Common Equity (ROCE)	-368.00%	-208.95%	-284.71%	-208.43%	-340.05%	-193.23%	-253.84%	-178.60%	-141.42%	-110.96%	-96.69%
Return on Equity Simple (ROE_SIMPLE)	-381.00%	0.00%	-161.17%	-135.31%	-437.28%	0.00%	-2,003.16%	-558.58%	-326.14%	0.00%	-144.63%
Net Operating Profit after Tax (NOPAT)	-100	-86	-92	-81	-116	-85	-102	-104	-108	-102	-158
NOPAT Margin	-71.83%	-51.91%	-66.23%	-55.40%	-106.35%	-67.06%	-103.59%	-95.62%	-107.34%	-98.64%	-173.69%
Net Nonoperating Expense Percent (NNEP)	-9.02%	-6.28%	-6.08%	-6.69%	-8.53%	-4.51%	-7.55%	-8.46%	-7.32%	-5.17%	-8.59%
Return On Investment Capital (ROIC_SIMPLE)	-69.37%	-33.53%	-	-	-	-31.02%	-	-	-	-28.92%	-
Cost of Revenue to Revenue	20.58%	10.25%	15.07%	14.47%	16.11%	9.46%	11.21%	9.15%	12.20%	5.15%	9.52%
SG&A Expenses to Revenue	63.03%	50.03%	57.60%	54.82%	71.82%	60.31%	76.41%	75.16%	76.27%	70.49%	77.00%
R&D to Revenue	119.01%	113.88%	121.95%	109.85%	164.00%	126.03%	160.37%	152.29%	164.88%	165.27%	261.62%
Operating Expenses to Revenue	182.04%	163.92%	179.55%	164.67%	235.82%	186.35%	236.77%	227.45%	241.15%	235.76%	338.62%
Earnings before Interest and Taxes (EBIT)	-142	-126	-129	-118	-167	-120	-146	-150	-154	-145	-226
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-135	-120	-123	-112	-162	-116	-141	-148	-152	-142	-221
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	23.22	15.22	14.76	7.90	27.33	14.26	80.36	25.32	12.77	9.21	6.19
Price to Tangible Book Value (P/TBV)	0.00	119.25	37.24	15.41	0.00	60.66	0.00	0.00	166.57	21.95	10.90
Price to Revenue (P/Rev)	5.67	6.93	9.79	7.10	8.66	9.04	6.21	8.11	7.33	8.94	8.45
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	4.73	5.62	8.23	5.28	7.38	7.25	4.93	6.56	5.46	6.47	5.50
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	136.23	0.00	81.49
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-3.88	-2.83	-3.51	-2.67	-3.57	-2.67	-3.07	-1.65	-1.51	-1.51	-1.45
Leverage Ratio	8.98	5.57	7.20	5.22	7.46	4.84	5.71	3.26	2.72	2.41	2.21
Compound Leverage Factor	9.47	5.90	7.44	5.77	7.60	5.11	6.22	3.46	2.89	2.54	2.34
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	4.63%	2.67%	1.98%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	95.37%	97.33%	98.02%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-2.19	-1.33	-0.42	-0.89	-1.60	-0.85	-2.15	-1.31	-1.14	-0.48	-0.43
Noncontrolling Interest Sharing Ratio	2.40%	1.30%	1.82%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.40	2.37	2.81	3.54	2.43	2.61	2.36	2.87	3.51	3.38	4.45
Quick Ratio	2.03	2.13	2.51	3.19	2.09	2.32	2.05	2.55	3.08	3.02	4.05
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-117	-105	-118	-134	-187	-128	-146	363	374	331	290
Operating Cash Flow to CapEx	-12,573.64%	-12,156.42%	-4,143.17%	-3,830.91%	-5,939.80%	-5,244.00%	-3,190.09%	-833.41%	-626.62%	-334.97%	-366.06%
Free Cash Flow to Firm to Interest Expense	-8.14	-6.74	-7.51	-8.41	-11.78	-7.39	-8.28	23.62	23.92	20.84	19.98
Operating Cash Flow to Interest Expense	-11.61	-5.12	-4.26	-4.82	-12.04	-4.84	-6.67	-7.56	-10.03	-5.69	-6.57
Operating Cash Flow Less CapEx to Interest Expense	-11.70	-5.16	-4.37	-4.95	-12.24	-4.93	-6.88	-8.46	-11.63	-7.39	-8.37
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.45	0.37	0.38	0.33	0.33	0.29	0.29	0.31	0.28	0.24	0.22
Accounts Receivable Turnover	5.93	5.74	6.06	5.45	6.18	7.63	7.43	7.48	10.76	10.55	12.14
Inventory Turnover	2.14	1.94	1.91	1.81	1.61	1.49	1.43	1.46	1.55	1.32	1.43
Fixed Asset Turnover	2.16	2.01	1.84	1.70	1.57	1.58	1.54	1.62	1.69	1.81	1.94
Accounts Payable Turnover	1.99	1.90	2.07	1.21	1.01	1.06	1.35	0.95	0.83	0.94	1.36
Days Sales Outstanding (DSO)	61.51	63.59	60.25	66.93	59.07	47.84	49.13	48.80	33.92	34.60	30.05
Days Inventory Outstanding (DIO)	170.20	187.85	190.75	201.80	226.02	245.18	254.47	249.26	235.16	277.08	254.99
Days Payable Outstanding (DPO)	183.67	192.35	176.06	300.74	361.32	344.69	269.83	385.64	437.58	389.31	269.23
Cash Conversion Cycle (CCC)	48.04	59.08	74.94	-32.01	-76.24	-51.68	33.77	-87.58	-168.50	-77.63	15.82
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-412	-483	-471	-442	-428	-502	-496	-495	-499	-544	-541
Invested Capital Turnover	-1.41	-1.14	-1.08	-1.03	-0.95	-0.83	-0.79	-1.54	-1.49	-1.11	-1.08
Increase / (Decrease) in Invested Capital	17	19	26	53	71	43	45	-467	-482	-433	-447
Enterprise Value (EV)	2,793	3,147	4,302	2,542	3,265	3,150	2,020	2,643	2,096	2,351	1,890
Market Capitalization	3,349	3,885	5,120	3,417	3,834	3,927	2,549	3,267	2,816	3,248	2,900
Book Value per Share	$1.56	$2.76	$3.76	$5.20	$1.66	$3.35	$0.44	$1.82	$3.14	$5.03	$6.69
Tangible Book Value per Share	($0.83)	$0.35	$1.49	$2.67	($0.82)	$0.79	($2.38)	($1.04)	$0.24	$2.11	$3.80
Total Capital	151	262	354	432	140	275	32	129	220	352	469
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-563	-745	-825	-874	-569	-777	-528	-624	-720	-897	-1,010
Capital Expenditures (CapEx)	1.32	0.65	1.62	2.01	3.21	1.60	3.70	14	25	27	26
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-87	-137	-107	-72	-62	-125	-97	-94	-81	-125	-103
Debt-free Net Working Capital (DFNWC)	407	473	515	692	350	452	345	458	548	623	785
Net Working Capital (NWC)	407	473	515	692	350	452	345	458	548	623	785
Net Nonoperating Expense (NNE)	51	48	41	50	55	38	58	56	56	50	88
Net Nonoperating Obligations (NNO)	-563	-745	-825	-874	-569	-777	-528	-624	-720	-897	-1,010
Total Depreciation and Amortization (D&A)	7.26	6.27	5.64	5.92	5.09	4.27	4.51	2.14	2.24	3.31	5.66
Debt-free, Cash-free Net Working Capital to Revenue	-14.72%	-24.46%	-20.47%	-14.97%	-13.94%	-28.89%	-23.62%	-23.39%	-21.15%	-34.42%	-30.10%
Debt-free Net Working Capital to Revenue	68.99%	84.42%	98.44%	143.73%	79.17%	104.03%	84.16%	113.63%	142.79%	171.38%	228.71%
Net Working Capital to Revenue	68.99%	84.42%	98.44%	143.73%	79.17%	104.03%	84.16%	113.63%	142.79%	171.38%	228.71%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.57)	($1.34)	($1.40)	($1.52)	($2.03)	($1.44)	($2.23)	($2.25)	($2.33)	($2.17)	($3.50)
Adjusted Weighted Average Basic Shares Outstanding	96.29M	90.54M	95.49M	86.58M	84.29M	73.54M	71.66M	70.90M	70.37M	69.91M	70.05M
Adjusted Diluted Earnings per Share	($1.57)	($1.34)	($1.40)	($1.52)	($2.03)	($1.44)	($2.23)	($2.25)	($2.33)	($2.17)	($3.50)
Adjusted Weighted Average Diluted Shares Outstanding	96.29M	90.54M	95.49M	86.58M	84.29M	73.54M	71.66M	70.90M	70.37M	69.91M	70.05M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	94.54M	92.50M	92.34M	92.17M	83.13M	82.34M	82.11M	71.49M	70.81M	70.22M	70.11M
Normalized Net Operating Profit after Tax (NOPAT)	-100	-86	-92	-81	-116	-85	-102	-104	-108	-102	-158
Normalized NOPAT Margin	-71.83%	-51.91%	-66.23%	-55.40%	-106.35%	-67.06%	-103.59%	-95.62%	-107.34%	-98.64%	-173.69%
Pre Tax Income Margin	-107.52%	-80.91%	-95.50%	-88.92%	-156.41%	-99.61%	-162.16%	-146.89%	-162.67%	-148.32%	-263.30%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-9.91	-8.11	-8.20	-7.41	-10.54	-6.93	-8.25	-9.75	-9.84	-9.16	-15.59
NOPAT to Interest Expense	-6.98	-5.51	-5.88	-5.10	-7.30	-4.93	-5.75	-6.74	-6.90	-6.42	-10.86
EBIT Less CapEx to Interest Expense	-10.00	-8.15	-8.31	-7.53	-10.74	-7.02	-8.46	-10.66	-11.44	-10.86	-17.39
NOPAT Less CapEx to Interest Expense	-7.07	-5.56	-5.98	-5.23	-7.51	-5.02	-5.96	-7.64	-8.50	-8.12	-12.66
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Ultragenyx Pharmaceutical's Financials

When does Ultragenyx Pharmaceutical's fiscal year end?

According to the most recent income statement we have on file, Ultragenyx Pharmaceutical's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Ultragenyx Pharmaceutical's net income changed over the last 9 years?

Ultragenyx Pharmaceutical's net income appears to be on an upward trend, with a most recent value of -$569.18 million in 2024, rising from -$145.62 million in 2015. The previous period was -$606.64 million in 2023. View Ultragenyx Pharmaceutical's forecast to see where analysts expect Ultragenyx Pharmaceutical to go next.

What is Ultragenyx Pharmaceutical's operating income?

Ultragenyx Pharmaceutical's total operating income in 2024 was -$535.97 million, based on the following breakdown:

Total Gross Profit: $483.50 million
Total Operating Expenses: $1.02 billion

How has Ultragenyx Pharmaceutical revenue changed over the last 9 years?

Over the last 9 years, Ultragenyx Pharmaceutical's total revenue changed from $0.00 in 2015 to $560.23 million in 2024, a change of 56,023,000,000.0%.

How much debt does Ultragenyx Pharmaceutical have?

Ultragenyx Pharmaceutical's total liabilities were at $1.24 billion at the end of 2024, a 2.1% increase from 2023, and a 4,258.2% increase since 2015.

How much cash does Ultragenyx Pharmaceutical have?

In the past 9 years, Ultragenyx Pharmaceutical's cash and equivalents has ranged from $93.57 million in 2015 to $713.53 million in 2020, and is currently $173.73 million as of their latest financial filing in 2024.

How has Ultragenyx Pharmaceutical's book value per share changed over the last 9 years?

Over the last 9 years, Ultragenyx Pharmaceutical's book value per share changed from 13.68 in 2015 to 2.76 in 2024, a change of -79.8%.

Related Companies

This page (NASDAQ:RARE) was last updated on 5/30/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ultragenyx Pharmaceutical (RARE) Financials

Frequently Asked Questions About Ultragenyx Pharmaceutical's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ultragenyx Pharmaceutical (RARE) Financials

Annual Income Statements for Ultragenyx Pharmaceutical

Quarterly Income Statements for Ultragenyx Pharmaceutical

Annual Cash Flow Statements for Ultragenyx Pharmaceutical

Quarterly Cash Flow Statements for Ultragenyx Pharmaceutical

Annual Balance Sheets for Ultragenyx Pharmaceutical

Quarterly Balance Sheets for Ultragenyx Pharmaceutical

Annual Metrics And Ratios for Ultragenyx Pharmaceutical

Quarterly Metrics And Ratios for Ultragenyx Pharmaceutical

Frequently Asked Questions About Ultragenyx Pharmaceutical's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools